-

Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2025 after the market closes on Thursday July 24, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com.

About Edwards Lifesciences

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

Contacts

Media Contact: Amy Meshulam, 949-250-4009
Investor Contact: Mark Wilterding, 949-250-6826

Industry:

Edwards Lifesciences Corporation

NYSE:EW
Release Versions
English

Contacts

Media Contact: Amy Meshulam, 949-250-4009
Investor Contact: Mark Wilterding, 949-250-6826

More News From Edwards Lifesciences Corporation

Edwards Lifesciences Reports Second Quarter Results

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and EVOQUE Q2 EPS of $0.572; adjusted1 EPS of $0.67 SAPIEN platform is only TAVR approved for asymptomati...

Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes

PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outco...

Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible lat...
Back to Newsroom